EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Moses Owoicho Abah iD, Deborah Oganya Ogenyi iD, Angelina V Zhilenkova, Freddy Elad Essogmo, Yvan Sinclair Ngaha Tchawe iD, Ikenna Kingsley Uchendu, Akaye Madu Pascal iD, Natalia M Nikitina iD, Alexander S Rusanov iD, Varvara D Sanikovich iD, Yuliya N Pirogova iD, Alexander Boroda iD und 2 weitere

International Journal of Molecular Sciences · 31.12.2024 · 26 (1) · 265

DOI: 10.3390/ijms26010265 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.12.2024. Verfasst von Moses Owoicho Abah und 13 weiteren Autor:innen. Beteiligte Einrichtung: World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow 119991, Russia. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Biomarkers, Tumor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A thorough study of Clear Cell Renal Cell Carcinoma (ccRCC) shows that combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) shows promising results in addressing the tumor-promoting influences of abnormal immunological and molecular biomarkers in metastatic Clear Cell Renal Cell Carcinoma (ccRCC). These abnormal biomarkers enhance drug resistance, support tumor growth, and trigger cancer-related genes. Ongoing clinical trials are testing new treatment options that appear more effective than earlier ones. However, more research is needed to confirm their long-term safety use and potential side effects. This study highlights vital molecular and immunological biomarkers associated with drug resistance in Clear Cell Renal Cell Carcinoma (ccRCC). Furthermore, this study identifies a number of promising drug candidates and biomarkers that serve as significant contributors to the enhancement of the overall survival of ccRCC patients. Consequently, this article offers pertinent insights on both recently completed and ongoing clinical trials, recommending further toxicity study for the prolonged use of this treatment strategy for patients with metastatic ccRCC, while equipping researchers with invaluable information for the progression of current treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorDrug Resistance, NeoplasmHumansProtein Kinase InhibitorsImmune Checkpoint InhibitorsMolecular Targeted TherapyNeoplasm MetastasisTherapies, Investigational

Stichwörter der Autor:innen

biomarkersccRCCdrug resistanceimmunotherapiesmetastasistargeted therapies

Substanzen

Biomarkers, TumorProtein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow 119991, Russia.
  • Department of Cancer Bioinformatics and Molecular Biology, Royal Society of Clinical and Academic Researchers (ROSCAR) International, Abuja 900104, Nigeria.
  • Medical Laboratory Science Department, Faculty of Health Science and Technology, College of Medicine, University of Nigeria, Enugu Campus, Enugu 410001, Nigeria.

ORCID-Profile: Moses Owoicho Abah, Deborah Oganya Ogenyi, Yvan Sinclair Ngaha Tchawe, Akaye Madu Pascal, Natalia M Nikitina, Alexander S Rusanov, Varvara D Sanikovich, Yuliya N Pirogova, Alexander Boroda

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Abah, M. O., Ogenyi, D. O., Zhilenkova, A. V., Essogmo, F. E., Ngaha Tchawe, Y. S., Uchendu, I. K., Pascal, A. M., Nikitina, N. M., Rusanov, A. S., Sanikovich, V. D., Pirogova, Y. N., Boroda, A., Moiseeva, A. V., & Sekacheva, M. I. (2024). Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC). International Journal of Molecular Sciences, 26(1), 265. https://doi.org/10.3390/ijms26010265

Vancouver

Abah MO, Ogenyi DO, Zhilenkova AV, Essogmo FE, Ngaha Tchawe YS, Uchendu IK, et al. Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC). International Journal of Molecular Sciences. 2024;26(1):265. doi:10.3390/ijms26010265

BibTeX
@article{Abah2024,
  author = {Abah, Moses Owoicho and Ogenyi, Deborah Oganya and Zhilenkova, Angelina V and Essogmo, Freddy Elad and Ngaha Tchawe, Yvan Sinclair and Uchendu, Ikenna Kingsley and Pascal, Akaye Madu and Nikitina, Natalia M and Rusanov, Alexander S and Sanikovich, Varvara D and Pirogova, Yuliya N and Boroda, Alexander and Moiseeva, Aleksandra V and Sekacheva, Marina I},
  title = {Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {26},
  number = {1},
  pages = {265},
  doi = {10.3390/ijms26010265}
}
Kostenlos starten →